<PAGE>
SCHEDULE 14A INFORMATION
Proxy Information Pursuant to Section 14(A) of the Securities Exchange Act of
1934
Filed by the Registrant (X)
Filed by a Party other than the Registrant ( )
Check the appropriate box:
( ) Preliminary Proxy Statement ( ) Confidential, for Use of
the Commission Only (as
permitted by Rule 14a-6(e)
(2))
(X) Definitive Proxy Statement
( ) Definitive Additional Materials
( ) Soliciting Materials Pursuant to (S) 240.14a-11(c) or (S) 240.14a-12
NEUROMEDICAL SYSTEMS, INC.
(NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
---------------------------
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
(X) No fee required
( ) $125 per Exchange Act Rules 0-11(c)(1)(ii), 14a-6(i)(1), or 14a-6(i)(2) or
Item 22(a) (2) of Schedule 14A
( ) $500 per each party to the controversy pursuant to Exchange Act Rule
14a-6(i)(3).
( ) Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11:(1) (Set forth the amount on
which the filing fee is calculated and state how it was
determined);
(4) Proposed maximum aggregate value of transaction.
(5) Total fee paid.
( ) Fee Paid previously with preliminary materials.
( ) Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement No.:
(3) Filing Party:
(4) Date Filed:
<PAGE>
Neuromedical Systems, Inc.
- ----------------------------------
Advancing the Vision of Cytology
Mark R. Rutenberg
Chairman, ---------
President / C.E.O. NSI[LOGO]
---------
April 15, 1997
Dear Stockholder:
You are cordially invited to the 1997 Annual Meeting of Stockholders of
Neuromedical Systems, Inc. (the "Company"), which will be held on Thursday, May
15, 1997 at 10:00 A.M. (Eastern standard time) at the Sheraton Crossroads Hotel
in Mahwah, New Jersey.
The Secretary's formal notice of the Annual Meeting and the Company's Proxy
Statement appear on the following pages and describe the matters to be acted
upon at the Annual Meeting. We urge you to read this information carefully.
Your Board of Directors believes that election of its nominees as directors and
ratification of its selection of independent auditors are in the best interests
of the Company and its stockholders and therefore recommends a vote FOR items 1
and 2 on the enclosed proxy card.
During the Annual Meeting, we will also review the Company's activities over the
past year and items of general interest about the Company. Management will also
respond to comments and questions from stockholders concerning the Company.
On behalf of the Company, I hope that you will be able to attend the Annual
Meeting. The Annual Meeting is an excellent opportunity for the Company's
management to discuss the Company's accomplishments with you in person. If you
cannot attend, please be sure to vote your preferences on the enclosed proxy
card and return it promptly. Returning the proxy card will not prevent you from
voting in person but will assure that your vote is counted if you are unable to
attend the Annual Meeting. WHETHER IN PERSON OR BY PROXY, IT IS IMPORTANT THAT
YOUR SHARES OF COMPANY COMMON STOCK BE REPRESENTED AND VOTED. ACCORDINGLY,
PLEASE COMPLETE, SIGN, DATE AND PROMPTLY RETURN THE ENCLOSED PROXY CARD IN THE
ACCOMPANYING PREPAID ENVELOPE. Thank you very much.
Sincerely,
/s/ Mark R. Rutenberg
Mark R. Rutenberg
<PAGE>
NEUROMEDICAL SYSTEMS, INC.
- --------------------------------------------------------------------------------
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON MAY 15, 1997
Notice is hereby given that the Annual Meeting of Stockholders of Neuromedical
Systems, Inc., will be held at the Sheraton Crossroads Hotel in Mahwah, New
Jersey, on Thursday, May 15, 1997 at 10:00 A.M. (Eastern standard time) for the
following purposes:
O TO ELECT TWO CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE YEAR 2000 ANNUAL
MEETING AND UNTIL THE ELECTION AND QUALIFICATION OF THEIR SUCCESSORS;
O TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT
AUDITORS FOR THE FISCAL YEAR ENDING DECEMBER 31, 1997; AND
O TO TRANSACT SUCH OTHER MATTERS AS MAY PROPERLY COME BEFORE THE ANNUAL
MEETING OR ANY ADJOURNMENT OR POSTPONEMENT THEREOF.
The foregoing items of business are discussed in greater detail in the Proxy
Statement accompanying this Notice.
Stockholders of record at the close of business (5:00 P.M., Eastern standard
time) on April 2, 1997, which the Board of Directors has designated as the
record date, are entitled to vote at the Annual Meeting or any adjournment or
postponement thereof. A list of these stockholders will be available for
inspection for ten days preceding the Annual Meeting at the office of the
Secretary at the principal executive offices of Neuromedical Systems, Inc., Two
Executive Boulevard, Suffern, New York, 10901-4164, and will also be available
for inspection at the Annual Meeting itself.
ALL STOCKHOLDERS ARE CORDIALLY INVITED TO ATTEND THE ANNUAL MEETING IN PERSON.
WHETHER OR NOT YOU PLAN TO ATTEND THE ANNUAL MEETING, PLEASE COMPLETE, SIGN,
DATE AND PROMPTLY RETURN THE ENCLOSED PROXY CARD IN THE ACCOMPANYING ENVELOPE
WHICH REQUIRES NO POSTAGE IF MAILED IN THE UNITED STATES. YOU MAY REVOKE YOUR
PROXY AT ANY TIME BEFORE IT IS VOTED, BY DELIVERY TO NEUROMEDICAL SYSTEMS, INC.
OF A SUBSEQUENTLY EXECUTED PROXY OR A WRITTEN NOTICE OF REVOCATION OR BY VOTING
IN PERSON AT THE ANNUAL MEETING. PLEASE NOTE, HOWEVER, THAT IF YOUR SHARES OF
COMPANY COMMON STOCK ARE HELD OF RECORD BY A BROKER, BANK OR OTHER NOMINEE AND
YOU WISH TO ATTEND AND VOTE AT THE ANNUAL MEETING, YOU MUST OBTAIN FROM SUCH
BROKER, BANK OR OTHER NOMINEE, A PROXY ISSUED IN YOUR NAME.
By order of the Board of Directors,
JOHN B. HENNEMAN, III
Vice President of Corporate Development,
Secretary and General Counsel
April 15, 1997
<PAGE>
NEUROMEDICAL SYSTEMS, INC.
TWO EXECUTIVE BOULEVARD, SUFFERN, NEW YORK 10901-4164
-------------------
PROXY STATEMENT
-------------------
This Proxy Statement is furnished in connection with the solicitation of
proxies by the Board of Directors of Neuromedical Systems, Inc. (the "Company").
The proxies will be voted at the Annual Meeting of Stockholders of the Company
on May 15, 1997 and at any adjournments or postponements thereof. Only holders
of Company common stock (the "Common Stock") of record at the close of business
(5:00 P.M., Eastern standard time) on April 2, 1997 (the "Record Date") are
entitled to notice of and to vote at the Annual Meeting. For each matter which
comes before the Annual Meeting, each share held is entitled to one vote. On the
Record Date there were 30,907,497 shares of Common Stock outstanding and
eligible to vote. This Proxy Statement and the proxy card are first being sent
on or about April 15, 1997 to each stockholder entitled to vote at the Annual
Meeting. Accompanying this Proxy Statement is the Company's annual report to
stockholders for the year ended December 31, 1996.
VOTING AND REVOCATION OF PROXIES
VOTING
If the enclosed proxy card is executed and returned on or prior to the
date of the Annual Meeting and not revoked, all shares of Common Stock
represented thereby will be voted. Each proxy will be voted as directed by the
stockholder or authorized representative. IF NO SUCH DIRECTION IS SPECIFIED,
SIGNED PROXY CARDS WILL BE VOTED FOR PROPOSALS 1 AND 2 IN ACCORDANCE WITH THE
RECOMMENDATION OF THE BOARD OF DIRECTORS.
All votes will be tabulated by the inspector of election appointed for
the Annual Meeting who will separately tabulate affirmative and negative votes,
abstentions and broker non-votes (i.e., shares held by a broker or nominee which
are represented at the Annual Meeting, but with respect to which such broker or
nominee is not empowered to vote on a particular proposal). The holders of a
majority of the shares of Common Stock entitled to vote at the Annual Meeting,
present (in person or by proxy), constitute a quorum. Under the Company's Bylaws
and Delaware law, shares represented by proxies that reflect abstentions or
broker non-votes will be counted as shares of Common Stock that are present and
entitled to vote for purposes of determining the presence of a quorum. The
affirmative vote of a plurality of the votes cast (in person or by proxy) at the
Annual Meeting will be required for the election of directors. Abstentions,
broker non-votes and withholding of authority to vote will have no affect on the
outcome of the election of directors. The two director nominees receiving the
highest number of votes shall be elected. With respect to all matters other than
the election of directors, the affirmative vote of a majority of the votes cast
(in person or by proxy) at the Annual Meeting, including abstentions, will be
required. Abstentions will have the effect of a vote "against" such other
matters. Broker non-votes will be excluded from the number of votes cast and
therefore will have the effect of reducing the number of affirmative votes
required to achieve the majority vote with respect to such other matters.
-3-
<PAGE>
REVOCATION
A stockholder giving a proxy may revoke it at any time before it is
voted, by delivery to the Company of a subsequently executed proxy or a written
notice of revocation or by voting in person at the Annual Meeting. Attendance at
the meeting will not, by itself, revoke a proxy. Returning your completed proxy
will not prevent you from voting in person at the Annual Meeting.
PROPOSAL 1
ELECTION OF DIRECTORS
The Board of Directors consists of three classes. Directors hold office
for staggered terms of three years and until their successors have been duly
elected and qualified. One of the three classes will be elected each year at the
Annual Meeting of Stockholders to succeed the directors whose terms are ending.
The directors in Class I and Class III are serving terms ending at the Annual
Meeting of Stockholders in 1999 and 1998, respectively.
Class II is currently comprised of three directors. One Class II
director is not standing for reelection when his term ends at the 1997 Annual
Meeting. In accordance with the Company's Amended and Restated Certificate of
Incorporation, the Board of Directors has determined that as of the election of
directors at the 1997 Annual Meeting, the authorized number of directors shall
be seven. Therefore, two directors in Class II are to be elected at the 1997
Annual Meeting. Proxies cannot be voted for more than two nominees. The Class II
directors so elected will hold office as directors until the year 2000 Annual
Meeting of Stockholders and until their respective successors have been duly
elected and qualified.
UNLESS OTHERWISE DIRECTED, ALL EXECUTED AND RETURNED PROXIES WILL BE
VOTED FOR THE NOMINEES LISTED BELOW. If any one or more of the nominees is
unable to serve for any reason or withdraws from nomination, proxies will be
voted for the substitute nominee or nominees, if any, proposed by the Board of
Directors. The Board of Directors has no knowledge that any nominee will or may
be unable to serve or will or may withdraw from nomination. Each of the Class II
nominees is currently serving as a director of the Company. Information is set
forth below concerning the Class II director nominees for terms ending at the
year 2000 Annual Meeting of Stockholders and the directors serving in Class I
and Class III.
NOMINEES FOR CLASS II DIRECTOR TERMS ENDING AT THE YEAR 2000 ANNUAL MEETING OF
STOCKHOLDERS
The affirmative vote of a plurality of the votes cast at the Annual
Meeting is required for the election of each nominee as a Class II director of
the Company. The following two nominees have been proposed by the Board of
Directors for election as Class II directors of the Company.
STUART M. ESSIG, age 35, has served as a director of the Company since
1993. Mr. Essig has been employed by the investment banking firm of Goldman,
Sachs & Co. since 1988 and, since 1996, has served as a Managing Director in
their Investment Banking Division, Healthcare Department.
-4-
<PAGE>
C. RAYMOND LARKIN, JR., age 48, has served as a director of the Company
since February 1996. Mr. Larkin has been an officer of Nellcor Puritan Bennett
Inc. and its predecessors since 1983, serving as Vice President, Sales and
Marketing and, since 1989, as President and Chief Executive Officer. Mr. Larkin
is a director of Nellcor Puritan Bennett Inc. and Arthrocare Corporation.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE IN FAVOR OF EACH NAMED NOMINEE SET
FORTH ABOVE IN PROPOSAL NUMBER 1.
CLASS I DIRECTORS WHOSE TERMS END AT THE 1999 ANNUAL MEETING OF STOCKHOLDERS
CARL GENBERG, age 45, has served as a director of the Company since 1990.
Mr. Genberg is currently President of Cytology West, Inc., which is the
territorial licensee of the PAPNET(R) technology for the states of Nevada,
Arizona, Utah and SaN Diego County, California. Until June 1993, Mr. Genberg was
General Counsel of the Company.
DR. ARTHUR L. HERBST, age 65, has served as a director of the Company since
the Annual Meeting of Stockholders held in June 1996. Dr. Herbst has served
since 1976 as Chairman, OB-GYN Department and Joseph Bolivar DeLee Distinguished
Service Professor, University of Chicago.
UZI ISH-HURWITZ, age 53, has served as a director of the Company since the
Annual Meeting of Stockholders held in June 1996. Mr. Ish-Hurwitz is Executive
Vice President and Chief of Technical Operations of the Company and President of
Neuromedical Systems Israel Ltd., a subsidiary of the Company. Mr. Ish-Hurwitz
joined the Company in April 1993 and, during the period from November 1992 to
April 1993, acted as an independent consultant. Mr. Ish-Hurwitz was the
co-founder of Indigo Graphic Systems, Ltd. (Rehovot, Israel) and served as its
President from 1987 to 1992. From 1973 to 1986, Mr. Ish-Hurwitz served as Vice
President-Operations of Scitex Corporation, Ltd. Mr. Ish-Hurwitz is also a
member of the board of directors of Breasy Medical Equipment (U.S.) Inc.
CLASS III DIRECTORS WHOSE TERMS END AT THE 1998 ANNUAL MEETING OF STOCKHOLDERS
MARK R. RUTENBERG, age 45, invented the PAPNET(R) Testing System in 1987
anD founded the Company in 1988. He has served as the Company's Chairman,
President and Chief Executive Officer since its inception. From 1980 to 1988,
Mr. Rutenberg was responsible for the management and marketing of several
advanced defense programs. Mr. Rutenberg is an inventor named in patents in the
areas of reliable system design, image analysis and cancer cell detection.
ELIZABETH COGAN FASCITELLI, age 38, has served as a director of the Company
since 1993. Ms. Fascitelli has been employed by the investment banking firm of
Goldman, Sachs & Co. since 1984 and, since 1988, has served as a Vice President
in their Investment Banking Division, Principal Investment Area. Ms. Fascitelli
also serves on the board of directors of Whole Foods Market, Inc.
Messrs. Rutenberg and Genberg are first cousins.
-5-
<PAGE>
FURTHER INFORMATION CONCERNING THE BOARD
OF DIRECTORS AND COMMITTEES
The Board of Directors of the Company directs the management of the
business and affairs of the Company, as provided by Delaware law. The Board of
Directors has two standing committees, the Audit Committee and the Compensation
Committee. From time to time, special committees may be established under the
direction of the Board of Directors when necessary to address specific issues.
The Company has no nominating or similar committee.
MEETINGS OF THE BOARD OF DIRECTORS AND COMMITTEES OF THE BOARD OF DIRECTORS
The Board of Directors held five meetings in 1996. Each incumbent
director participated in 75% or more of the aggregate number of such meetings of
the Board of Directors and meetings of the respective committees on which each
such director served during his or her term as a director during 1996.
The Audit Committee's principal functions are to meet with the Company's
independent accountants to review the Company's internal controls and financial
management practice, review the annual audit of the Company by its independent
auditors, review the annual financial statements of the Company and the related
audit report of the Company as prepared by the independent auditors, recommend
the selection of independent auditors each year and review audit and any
non-audit fees paid to the Company's independent auditors. The Audit Committee
reports its finding and recommendations to the Board of Directors for
appropriate action. The Audit Committee held three meetings in 1996. The 1996
Audit Committee was composed of three non-employee directors, Stuart M. Essig,
C. Raymond Larkin, Jr. and Stephen K.C. Ng, M.D., each of whom is continuing to
serve as a member of the Audit Committee as of the date of this Proxy Statement.
The Compensation Committee recommends to the Board of Directors
compensation for the Company's employees. The Compensation Committee held two
meetings in 1996. The 1996 Compensation Committee was composed of three
non-employee directors, Elizabeth Cogan Fascitelli, Carl Genberg and Arthur L.
Herbst, M.D., each of whom is continuing to serve as a member of the
Compensation Committee as of the date of this Proxy Statement. Discussion of the
Compensation Committee's recommendations may be found below under the caption
"Report on 1996 Executive Compensation."
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
Decisions with respect to compensation for the 1996 fiscal year were
made by the entire Board of Directors on the recommendation of the Compensation
Committee. Members of the Compensation Committee are outside directors who are
not officers or employees of the Company or its subsidiaries and are not
eligible to participate in any of the plans or programs that the committee
administers.
The Company has entered into consulting agreements with various
individuals prominent in the field of cytology, pathology and gynecologic
oncology, including Dr. Arthur L. Herbst, a director who serves on the
Compensation Committee. Dr. Herbst's consulting agreement provides the Company
with additional intellectual resources in the areas of product development,
commercialization and clinical studies of the PAPNET(R) Testing System. Dr.
Herbst's current consulting agreement provides for an annual base fee of $20,000
plus expenses and additional fees for special projects. The term of his
agreement ends on December 31, 1999. The Company paid Dr. Herbst approximately
$36,000, $27,500 and $20,000 in 1996, 1995 and 1994, respectively, plus
reimbursement of expenses incurred in connection with such services. The Company
believes that the terms of Dr. Herbst's consulting agreement are no less
favorable than the terms it has received for similar agreements entered into
with parties unaffiliated with the Company.
-6-
<PAGE>
From 1989 through 1991, the Company sold various long-term territorial
license agreements (the "License Agreements") for the PAPNET(R) Testing System.
Following mergers of the various entities holding the License Agreements, there
are currently two licensees. Carl Genberg, a director of the Company and member
of the Compensation Committee, has significant ownership interests in the two
licensees and is an officer and director of Cytology West, Inc., holder of the
License Agreement relating to Arizona, Nevada, Utah and San Diego County. In
connection with 1995 Settlement and Warrant Exercise Agreements with the
licensees, which clarified previously disputed elements of the License
Agreements, Mr. Genberg received 26,903 shares of Common Stock upon the
"cashless exercise" of certain warrants (such warrants had originally been
issued to an affiliate of Mr. Genberg in consideration of instrumental
assistance to the Company with respect to sales of the License Agreements). In
addition, the Company issued 89,020 shares of Common Stock pursuant to the
Settlement Agreement as an aggregate distribution to certain of the licensees
and to Mr. Genberg individually. The holders of the License Agreements receive
royalties on an annual basis which the Company estimates will be approximately
10% of its United States revenues over the term of the License Agreements, but
there is no assurance that the amount of such royalties will not be more or less
than such percentage. The Company's aggregate royalty expense incurred under the
License Agreements was approximately $286,000 and $87,000 in 1996 and 1995,
respectively. In accordance with the Settlement Agreement, the Company will
enter into revised licenses with the two licensees pursuant to which the rights
and obligations will be clarified but as to which the economic terms will not be
materially altered except that slides received from multistate national
laboratories will be deemed to have been received from the licensed territories
pro rata according to each territory's population as a percentage of United
States population. The Restated Licenses will expire on December 31, 2025. The
Company believes that the terms of the foregoing transactions involving Mr.
Genberg are no less favorable to the Company than the terms it received for
similar transactions entered into with unaffiliated licensees of the Company.
The Board of Directors are of the opinion that the business
arrangements of Dr. Herbst and Mr. Genberg do not affect their respective
objectivity or performance as members of the Compensation Committee. In the
opinion of the Board of Directors, all of the directors serving on the
Compensation Committee are independent of management and free of any
relationship that would interfere with their exercise of independent judgment.
COMPENSATION OF DIRECTORS
The Company's 1993 Stock Incentive Plan, as amended and restated October
25, 1995 (the "Incentive Plan") provides for the non-discretionary grant of
options to each of the Company's non-employee directors ("Director Options") of
(i) 2,500 shares of Common Stock to each non-employee director who becomes a
member of the Board of Directors after October 25, 1995 upon election or
appointment and (ii) an additional 2,500 shares of Common Stock, annually on the
first business day following the annual meeting of the stockholders to those
non-employee directors who are members of the Board of Directors at that time.
The exercise price of such options granted under the Incentive Plan is set at
the closing price of publicly traded Common Stock on the day immediately
preceding the grant date. The options granted under the Incentive Plan vest six
months and one day following the date of grant.
The members of the Board of Directors receive reimbursement of their
expenses incurred in connection with attendance at Board of Directors and
committee meetings.
Effective as of June 20, 1996, the Company compensation to non-employee
directors consists of an annual retainer of $6,000, a fee of $1,000 for each
meeting attended on location ($500 for telephonic meetings), $500 for Board of
Directors committee meetings held on the same day as a Board meeting and $1,000
for committee meetings which are held on separate days from Board meetings ($500
for telephonic committee meetings).
-7-
<PAGE>
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT
The following table sets forth, as of the close of business March 31,
1997 (unless otherwise noted), information regarding the beneficial ownership of
the Company's Common Stock by (i) directors, (ii) the Company's Chief Executive
Officer and seven of the Company's most highly compensated executive officers
for the fiscal year ended December 31, 1996, (iii) all directors and executive
officers of the Company as a group and (iv) each person or entity known by the
Company to beneficially own 5% or more of the outstanding shares of Common
Stock.
<TABLE>
<CAPTION>
Amount
Title of Class Name and Address of Beneficial Beneficially Percent of Class
Owner Owned (1)
- -------------- ------------------------------ -------------- ----------------
<S> <C> <C> <C>
Common Stock The Goldman Sachs Group, L.P. 7,920,199 25.23%
and related investors (2)
85 Broad Street
New York, NY 10004
Common Stock H&S Trust and related investors (3) 3,751,676 12.14%
Suite 3C, Centre Plaza
Horseback Lane
Gibraltar
Common Stock Edelson Technology 1,796,465 5.81%
Partners II, L.P. (4)
Whiteweld Centre
Woodcliff Lake, NJ 07675
Common Stock Putnam Investment Management (5) 2,499,731 8.09%
One Post Office Square
Boston, MA 02109
Common Stock Mark R. Rutenberg (6) 1,493,804 3.16%
Common Stock Stuart M. Essig (7) 5,000 *
Common Stock Elizabeth Cogan Fascitelli (7) 5,000 *
Common Stock Carl Genberg (8) 45,851 *
Common Stock Arthur L. Herbst, M.D. (9) 9,800 *
Common Stock C. Raymond Larkin, Jr. (10) 5,000 *
Common Stock Stephen K.C. Ng, M.D. (11) 305,445 *
Common Stock Uzi Ish-Hurwitz (12) 111,298 *
Common Stock David Duncan, Jr. (13) 53,268 *
Common Stock Zeev Hadass (14) 64,000 *
Common Stock John B. Henneman, III (15) 82,614 *
Common Stock James M. Herriman (16) 90,305 *
Common Stock Laurie J. Mango, M.D. (17) 112,464 *
Common Stock Andrew C. Panagy (18) 83,468 *
Common Stock All directors and executive
officers as a group (16 persons,
including the individuals listed 2,522,588 4.44%
above) (19)
</TABLE>
* Less than 1% beneficial ownership.
(1) The words "group" and "beneficial" are as defined in regulations issued by
the Securities and Exchange Commission (the "Commission"). Beneficial ownership
under such definition means possession of sole or shared voting power, or sole
or shared dispositive power. Except as indicated in the footnotes to this table,
the persons named have sole voting and investment power with respect to all
shares of Common Stock shown as beneficially owned by them.
-8-
<PAGE>
(2) Based on information provided to the Company dated February 28, 1997.
Includes shares of Common Stock beneficially owned by certain investment limited
partnerships of which affiliates of The Goldman Sachs Group, L.P. ("GS Group")
are the general partners or the managing general partners. GS Group owns 125,000
shares of Common Stock. Also includes 1,055,225 shares of Common Stock held in
managed accounts ("Managed Accounts") for which Goldman, Sachs & Co. exercises
voting or investment authority, or both and 1,688 shares of Common Stock
acquired in the ordinary course of business by Goldman, Sachs & Co. Also
includes options exercisable for 10,000 shares of Common Stock in respect of Ms.
Fascitelli's and Mr. Essig's service on the Board of Directors which are
beneficially owned by GS Group. GS Capital Partners, L.P. ("GSCP") beneficially
owns 5,382,629 shares of Common Stock; Stone Street Fund 1993, L.P. ("Stone
Street") beneficially owns 635,958 shares of Common Stock; and Bridge Street
Fund 1993, L.P. ("Bridge Street," and together with Stone Street and GSCP, the
"Limited Partnerships") beneficially owns 709,699 shares of Common Stock. The
foregoing amounts reported as beneficially owned by the Limited Partnerships
include an aggregate of 87,328 shares of Common Stock which are subject to the
exercise of options and warrants. GS Group disclaims beneficial ownership of
shares of Common Stock held (i) by the Limited Partnerships to the extent
partnership interests in such partnerships are held by persons other than GS
Group and its affiliates and (ii) in Managed Accounts. GS Group shares voting
and dispositive power with respect to all shares reported as beneficially owned,
other than the 125,000 shares and the 10,000 options beneficially owned by GS
Group.
(3) Based on Schedule 13-G/A filed with the Commission on February 13, 1997 by
H&S Trust with respect to H&S Trust's beneficial ownership of an aggregate of
3,751,676 shares of the Company's Common Stock held of record by three
Netherlands Antilles corporations: Leadville A.V.V., Tehila Holdings A.V.V. and
Marineland A.V.V. H&S Trust is the sole stockholder of such corporations.
Included in such shares beneficially owned by H&S Trust, Leadville A.V.V. is the
holder of record of 1,815,642 shares of Common Stock which represent 5.35% of
the Company's outstanding shares. H&S Trust has sole voting and sole dispositive
power with respect to all shares which it beneficially owns.
(4) Based on information provided to the Company dated as of February 28, 1997.
Includes 216,650 shares of Common Stock held of record by Edelson Technology
Partners III, L.P., a limited partnership under common control with Edelson
Technology Partners II, L.P.
(5) Based on Schedule 13-G filed with the Commission by Putnam Investment, Inc.
("PI") on behalf of itself, Marsh & McLennan Companies, Inc. ("MMC"), Putnam
Investment Management, Inc. ("PIM") and The Putnam Advisory Company, Inc.
("PAC") on January 27, 1997. PI reported an aggregate beneficial ownership of
2,499,731 shares, over which it has shared voting power of 34,500 shares, shared
dispositive power of 2,499,731 shares and no sole voting power. PIM reported an
aggregate beneficial ownership of 2,437,631, over which it has shared
dispositive power of 2,437,631 shares and no sole voting power. PAC reported
aggregate beneficial ownership of 62,100 shares over which it had shared voting
power of 34,500 shares, shared dispositive power of 62,100 shares and no sole
voting power. MMC reported beneficial ownership of no shares of Common Stock and
no sole or shared voting or dispositive power of any Common Stock.
(6) Includes an option exercisable for 500,000 shares of Common Stock. Such
amount does not include the performance-based option which becomes exercisable
under certain circumstances for 813,273 shares of Common Stock (described below
in footnote 2 under "Summary Compensation Table").
-9-
<PAGE>
(7) Includes options exercisable for 5,000 shares of Common Stock granted
in respect of each of Mr. Essig's and Ms. Fascitelli's service on the Board of
Directors. Mr. Essig and Ms. Fascitelli are officers of Goldman, Sachs & Co.
Share data shown for such individuals excludes shares and options for Common
Stock shown as held by The Goldman Sachs Group, L.P. and related investors set
forth above in footnote 2. Each of Mr. Essig and Ms. Fascitelli has an
understanding with the Goldman Sachs Group, L.P., pursuant to which they hold
their respective stock options for the benefit of the GS Group. Each of Mr.
Essig and Ms. Fascitelli do not have any pecuniary interest in the stock options
and, accordingly, each disclaim beneficial ownership.
(8) Includes options exercisable for 5,000 shares of Common Stock granted
in respect of Mr. Genberg's service on the Board of Directors.
(9) Includes 800 shares of Common Stock held by Dr. Herbst's wife as to which
shares Dr. Herbst disclaims beneficial ownership. Includes options exercisable
for 5,000 shares of Common Stock granted in respect of Dr. Herbst's service on
the Board of Directors.
(10) Includes options exercisable for 5,000 shares of Common Stock granted in
respect of Mr. Larkin's service on the Board of Directors.
(11) Includes (i) 25,000 shares of Common Stock issuable upon exercise of
warrants held of record by Dr. Ng, (ii) 1,562 shares of Common Stock issuable
upon exercise of warrants held of record jointly with Dr. Ng's wife, (iii)
231,383 shares of Common Stock owned of record by Papnet (Far East) Ltd. (of
which Dr. Ng owns 18.3% and as to such shares of Common Stock Dr. Ng disclaims
beneficial ownership), (iv) 42,500 shares of Common Stock held of record by
Bluehill Holdings, Ltd., a corporation over which Dr. Ng has voting control and
(v) options exercisable for 5,000 shares of Common Stock granted in respect of
Dr. Ng's service on the Board of Directors. Dr. Ng's term as a Class II Director
ends at the 1997 Annual Meeting and he is not standing for reelection.
(12) Includes options exercisable for 104,870 shares of Common Stock.
(13) Includes options exercisable for 50,000 shares of Common Stock.
(14) Includes options exercisable for 56,000 shares of Common Stock.
(15) Includes 750 shares of Common Stock owned by the spouse and children
of Mr. Henneman, as to which shares Mr. Henneman disclaims beneficial ownership.
Includes options exercisable for 77,000 shares of Common Stock.
(16) Includes options exercisable for 85,000 shares of Common Stock.
(17) Includes options exercisable for 106,250 shares of Common Stock.
(18) Includes options exercisable for 80,000 shares of Common Stock.
(19) The shares of Common Stock shown with respect to directors and officers
include options exercisable within 60 days for an aggregate of 1,087,120 shares
of Common Stock at exercise prices ranging from $4.00 to $22.63 per share, all
of which shares of Common Stock were deemed outstanding for purposes of
computing the percentage of shares of Common Stock outstanding and beneficially
owned. Directors and officers also hold options that are not presently
exercisable with respect to an additional 1,146,603 shares of Common Stock
which, in accordance with the rules of the Commission, are not included in the
table.
-10-
<PAGE>
EXECUTIVE COMPENSATION
SUMMARY COMPENSATION TABLE
The Summary Compensation Table below provides certain compensation
information for the Chief Executive Officer and seven of the Company's most
highly compensated executive officers (six of whom earned equivalent
compensation during fiscal year 1996) serving at the fiscal year ended December
31, 1996 (collectively, the "Named Executive Officers") for services rendered in
all capacities during the fiscal years ended December 31, 1996, 1995 and 1994.
The table includes the dollar value of base salary, bonuses earned, option
awards (shown in number of shares of Common Stock) and certain other
compensation, whether paid or deferred. Bonus amounts awarded with respect to
1996 compensation were granted in February 1997.
<TABLE>
<CAPTION>
Annual Long-Term
Compensation Compensation Awards
----------------------- ----------------------------------
Other Securities
Annual Underlying All other
Name and Compen- Restricted Options/SARs Compen-
Principal Position Year Salary Bonus sation (1) Stock (#) sation (1)
---------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C>
Mark R. Rutenberg...... 1996 $175,000 $ 25,00 -- -- -- --
Chairman of the Board, 1995 175,000 131,000 -- -- 813,273 (2) --
President and 1994 175,000 50,000 -- -- --
Chief Executive
Officer
Uzi Ish-Hurwitz........ 1996 150,000 25,000 -- -- --
Executive Vice 1995 150,000 90,000 (3) -- -- -- --
President and Chief 1994 150,000 33,300 -- -- --
of Technical
Operations; President,
NSI (Israel) Ltd.;
director
David Duncan, Jr....... 1996 125,000 25,000 -- -- -- --
Vice President, 1995 125,000 45,750 (3) -- -- -- --
Finance and 1994 14,263 -- -- -- -- --
Administration
and Chief Financial
Officer
Zeev Hadass............ 1996 125,000 25,000 -- -- --
Vice President, 1995 125,000 -- -- -- 50,000 (4)
Processing 1994 36,458 -- -- -- 50,000 (5)
Operations
John B. Henneman, III.. 1996 125,000 25,000 -- -- -- --
Vice President of 1995 125,000 57,600 (3) -- -- 25,000 (6) --
Corporate 1994 104,167 -- -- -- 75,000 (7) --
Development, Secretary
and General
Counsel
James M. Herriman...... 1996 125,000 25,000 -- -- -- --
Vice President of 1995 125,000 68,400 (3) -- -- -- --
Product 1994 129,167 -- -- -- -- --
Development
Laurie J. Mango, M.D. . 1996 125,000 25,000 -- -- -- --
Vice President 1995 125,000 80,000 (3) -- -- -- --
and Medical Director 1994 129,167 -- -- -- -- --
Andrew C. Panagy....... 1996 125,000 25,000 -- -- -- --
Vice President, 1995 125,000 45,750 (3) -- -- -- --
Marketing 1994 110,322 -- -- -- -- --
and Sales
</TABLE>
(1) Excludes certain perquisites which do not exceed the lesser of $50,000 or
10% of the Named Executive Officer's aggregate salary and bonus.
-11-
<PAGE>
(2) The Company granted to Mr. Rutenberg a performance-based option under the
Incentive Plan exercisable under certain conditions for 813,273 shares of Common
Stock (the "Performance Based Option"). The following description of the
Performance Based Option is qualified in its entirety by reference to the
complete Incentive Plan, a copy of which has been filed with the Commission as
an exhibit among the Company's required filings pursuant to federal securities
laws. The Performance Based Option may be exercised at a price equal to the
Company's initial public offering price of the Common Stock ($15.00 per share)
and covers 813,273 shares of Common Stock which is designed to produce an option
value of $12.5 million if at any time during the option's ten-year term either
of the following events (the "Performance Goal") occurs: (i) the Company's share
price over any 90 consecutive day period reaches $30.37 (the "Target Price") or
(ii) all or substantially all of the Company's shares of Common Stock are
acquired (an "Acquisition") at or above the Target Price. If the Performance
Goal is attained, the option will become exercisable as to one-third of the
number of shares of Common Stock subject thereto on the later of (i) December 7,
1998 or (ii) the date that the Performance Goal is attained (the "Initial
Vesting Date"), and will become exercisable as to an additional one-third of the
shares of Common Stock subject thereto on each of the first two anniversaries of
the Initial Vesting Date; provided, however, that, if Mr. Rutenberg's employment
is terminated by the Company without cause following an Acquisition that occurs
following or simultaneously with the attainment of the Performance Goal, the
option will be fully exercisable. No additional vesting will occur following Mr.
Rutenberg's termination of employment under any other circumstances or the
expiration of the option's ten-year term. Following Mr. Rutenberg's termination
of employment by the Company for any reason other than for cause, the option, to
the extent vested and exercisable at the time of such termination, may be
exercised within six months of the termination of employment. The option
provides for equitable adjustments to the Performance Goal, the number of shares
of Common Stock subject to the option and the exercise price in the event of a
corporate change in capitalization. The exercisability of the option will not
accelerate upon the occurrence of a corporate change in control, and the option
will terminate in connection with an Acquisition if the Performance Goal is not
attained prior to or in connection with the Acquisition.
(3) One-half of the bonus amounts shown were paid, at the election of the named
individual, in the form of shares of Common Stock at a fair market price of
$7.00 per share, which in the aggregate amounted to 17,136 shares issued by the
Company.
(4) Option grant vests 20% at each anniversary of the date of grant and becomes
fully vested in the year 2000; each option is exercisable at $7.00 per share of
Common Stock.
(5) Options are fully vested and exercisable at $4.00 per share of Common Stock.
(6) Option grant vests 20% at each anniversary of the date of grant and becomes
fully vested in the year 2000; each option is exercisable for $6.00 per share of
Common Stock.
(7) Options are fully vested and exercisable at $4.00 per share of Common Stock.
-12-
<PAGE>
OPTION GRANTS IN 1996 FISCAL YEAR
The following chart summarizes the stock options granted during fiscal
year 1996 to the Named Executive Officers. No stock options were granted to the
Named Executive Officers during the fiscal year ended December 31, 1996.
<TABLE>
<CAPTION>
Potential Realizable Value at
Assumed Annual Rates of Stock
Price Appreciation
Individual Grants for Option Term (1)
-------------------------------------------- ---------------------------------
% of Total
Number of Options
Securities Granted to
Underlying Employees Exercise
Options in Fiscal or Base Expiration
Name Granted Year Price Date 5% 10%
---- ------- ---- ----- ---- -- ---
<S> <C> <C> <C> <C> <C> <C>
Mark R. Rutenberg..... 0 0% - - - -
Uzi Ish-Hurwitz....... 0 0% - - - -
David Duncan, Jr...... 0 0% - - - -
Zeev Hadass .......... 0 0% - - - -
John B. Henneman, III. 0 0% - - - -
James M. Herriman..... 0 0% - - - -
Laurie J. Mango, M.D.. 0 0% - - - -
Andrew C. Panagy...... 0 0% - - - -
</TABLE>
(1) These columns show the hypothetical gains or "option spreads" of the
outstanding options granted based on assumed annual compound stock appreciation
rates of 5% and 10% over the options' terms. The 5% and 10% assumed rates of
appreciation are mandated by the rules of the Commission and do not represent
the Company's estimate or projections of future prices of the Company's Common
Stock.
-13-
<PAGE>
AGGREGATED OPTION EXERCISES IN FISCAL YEAR 1996 AND FISCAL YEAR-END 1996 OPTION
VALUES
The following table sets forth certain information regarding exercised
options and the number of shares of Common Stock covered by both exercisable and
unexercisable options on Common Stock held by the Named Executive Officers as of
December 31, 1996. Each of these options was granted at exercise prices ranging
from $4.00 to $15.00 per share. Each is a non-qualified option with a ten-year
term, subject to earlier termination in the event of the optionee's termination
of employment. The unexercisable options granted to Mark R. Rutenberg are
subject to vesting in accordance with the terms of the Performance Based Option,
described in footnote 2 of the Summary Compensation Table above.
<TABLE>
<CAPTION>
Number of Securities Value of Unexercised
Underlying Unexercised In-the-Money
Options at Options at
Fiscal Year-End Fiscal Year-End(1)
-------------------------------- ---------------------------------
Shares Value
Acquired on Realized
Name Exercise (#) ($)(2) Exercisable Unexercisable Exercisable Unexercisable
- -----------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Mark R. Rutenberg................ 0 $ 0 500,000 813,273 $4,625,000 $ 0
Uzi Ish-Hurwitz.................. 22,130 291,529 102,870 0 951,548 0
David Duncan, Jr................. 50,000 501,250 50,000 0 362,500 0
Zeev Hadass ..................... 4,000 48,000 56,000 40,000 500,000 250,000
John B. Henneman, III............ 8,000 107,062 72,000 20,000 656,000 145,000
James M. Herriman................ 15,000 195,600 85,000 0 786,250 0
Laurie J. Mango, M.D............. 18,750 195,600 106,250 0 982,813 0
Andrew C. Panagy ................ 20,000 272,400 80,000 0 740,000 0
</TABLE>
- --------
(1) Values for "in-the-money" outstanding options represent the positive spread
between the respective exercise prices of the outstanding options and the market
value of the Common Stock as of December 31, 1996, which was $13.25.
(2) Value realized is based on the market value of the Company's Common Stock on
the date of exercise, minus the exercise price, and does not necessarily
indicate that the optionee sold such stock.
EMPLOYMENT AGREEMENTS
As of the date of this Proxy Statement, of the Named Executive Officers
only Mark R. Rutenberg and David Duncan, Jr. have employment agreements with the
Company.
The employment agreement for Mr. Rutenberg commenced in November 1993
and is for a five-year term. The employment agreement for Mr. Rutenberg provides
for an annual base salary subject to review at least annually with a view to the
increase thereof based on the employee's and the Company's performance,
inflation, industry salary scales and other relevant factors. Pursuant to the
terms of Mr. Rutenberg's employment agreement, he has received options to
purchase a designated number of shares of Common Stock under the Incentive Plan.
His employment agreement was amended as of October 25, 1995 to provide that, in
the event
-14-
<PAGE>
that he is terminated other than for "Cause" or "Disability" (as those
terms are defined in his employment agreement), and also if he terminates for
"Good Reason" (as defined in his employment agreement), a portion of his stock
options will become vested and exercisable to the extent that it would have
become vested and exercisable had he remained employed by the Company for a
one-year period following his termination of employment, subject to compliance
with the restrictive covenants in his employment agreement. Options held by Mr.
Rutenberg as of the date of the termination of employment (other than his
Performance Based Option, described in footnote 2 of the Summary Compensation
Table above) will remain exercisable (to the extent those options either are
vested on termination of employment or become vested over the succeeding year)
until the earlier of the date one year following the termination of employment
or the expiration of the options' respective terms. "Good Reason" is defined for
purposes of Mr. Rutenberg's employment agreement to include (i) any circumstance
that has the effect of significantly reducing Mr. Rutenberg's duties or
authority, (ii) a breach by the Company of its material obligations under the
employment agreement, (iii) the relocation of the principal executive offices of
the Company in excess of 35 miles from their present location not consented to
by Mr. Rutenberg, (iv) the occurrence of a "Change in Control" as defined in the
Incentive Plan in a transaction to which Mr. Rutenberg does not consent, (v) the
disposition by the Company (whether direct or indirect, by sale of assets or
stock, merger, consolidation or otherwise) of all or substantially all of its
business and/or assets in a transaction to which Mr. Rutenberg does not consent
or (vi) any circumstance whereby, without Mr. Rutenberg's consent, any of the
Company's offices or facilities is caused to operate on the Jewish Sabbath or on
any Jewish holiday, and as a result thereof, Mr. Rutenberg reasonably determines
that he would be prohibited under Jewish law from continuing as the Chief
Executive Officer of the Company, provided that any of the events described in
clauses (i), (ii) or (vi) will constitute Good Reason only if Mr. Rutenberg has
notified the Board of Directors in writing of the existence and particulars of
such circumstance and the Board of Directors has failed to remedy such
circumstance within thirty days of such notice.
Mr. Rutenberg's employment agreement provides that, in addition to his
base salary, Mr. Rutenberg will be entitled to an annual bonus in an amount to
be determined at the discretion of the Board of Directors, subject to
performance objectives established by the Board of Directors, and the use of a
Company-provided car. The employment agreement provides that, in the event that
Mr. Rutenberg's employment is terminated by the Company other than for "Cause"
or "Disability" or by Mr. Rutenberg for "Good Reason," the Company will (i) pay
Mr. Rutenberg a lump sum severance amount equal to 2.99 times his annual base
salary in effect as of the date of such termination and (ii) continue the
health, accident and life insurance benefits and other disability plans and
programs provided to him immediately prior to such termination for the shorter
of one year or the balance of the term of his employment agreement. If Mr.
Rutenberg's employment is terminated by the Company for Cause or by Mr.
Rutenberg without Good Reason, Mr. Rutenberg will be entitled to receive his
salary through his date of termination, and his entitlement to any other
compensation or benefits beyond the term of his employment will be determined in
accordance with the Company's general plans, policies and practices as in effect
from time to time. If Mr. Rutenberg's employment is terminated due to his death,
the Company will continue, for the shorter of one year following his death or
the balance of the term of his employment agreement, the health, accident and
life insurance benefits and other disability plans and programs provided to his
dependents immediately prior to his death. If Mr. Rutenberg's employment is
terminated due to Disability (as defined in his employment agreement), for the
shorter of one year following his termination or the balance of the term of his
employment agreement, the Company will (i) continue to pay his salary, reduced
by the amount of his disability benefits, if any, and (ii) continue the health,
accident and life insurance benefits and other disability plans and programs
provided to Mr. Rutenberg immediately prior to such
-15-
<PAGE>
termination. If necessary, the payments and benefits provided above will be
reduced to the extent required so that no payment to Mr. Rutenberg will be an
"excess parachute payment" under the Internal Revenue Code of 1986, as amended
(the "Code") Section 280G.
Under his employment agreement, Mr. Rutenberg has assigned to the
Company all rights to inventions, discoveries, improvements and patentable and
copyrightable works conceived by him in the course of his employment with the
Company and related to the business or activities of the Company. Mr. Rutenberg
has agreed not to disclose to others trade secrets and other confidential
information of the Company during the term of his employment and for a five-year
period thereafter. Mr. Rutenberg has also agreed that, during the term of his
employment under his employment agreement and for a period of three years
thereafter, he will not engage in activity which is competitive with the
business of the Company; however, in the event that his employment is terminated
without Cause or he terminates his employment for Good Reason, the
non-competition period is reduced to two years.
Mr. Duncan's employment agreement contains provisions generally similar
to those in Mr. Rutenberg's employment agreement, except that (i) upon a
voluntary termination of employment for good reason, the entitlement to any
other compensation or benefits shall be determined in accordance with the
Company's plans, policies and practices as in effect from time to time, (ii)
upon a termination of employment by the Company without Cause, for a period of
one year thereafter Mr. Duncan will be entitled to continue to receive his base
salary in effect at the time of termination and continued coverage under health,
accident and life insurance and other disability plans and programs, (iii) the
non-competition restriction is for a two-year period following termination of
his employment and (iv) there is no provision for a reduction under Code Section
280G, but the severance payments provided under the employment agreement will be
reduced by any income received from other sources during such severance period.
CONSULTING AGREEMENTS
The Company has entered into consulting agreements with various
individuals prominent in the field of cytology, pathology and gynecologic
oncology, including Dr. Arthur Herbst who serves on the Board of Directors.
These agreements provide the Company with additional intellectual resources in
the areas of product development and clinical studies of the PAPNET(R) Testing
System's performance. In addition, certain of these consultants are providing
services to the Company in connection with its introduction of the PAPNET(R)
Testing System.
-16-
<PAGE>
REPORT ON 1996 EXECUTIVE COMPENSATION
The Company's executive compensation programs are designed to attract,
retain and motivate the executive talent required to achieve the Company's
business objectives and increase stockholder value. The 1996 compensation
programs for the Company's executive officers (the "Management") were
administered by the entire Board of Directors, based upon the recommendations of
the Compensation Committee.
GENERAL
Under the Company's compensation policies relating to Management, total
compensation for each member of Management consists of a base salary and may
also include an annual cash bonus and long-term incentives, which may include
stock options, stock appreciation rights, dividend equivalent rights, restricted
and unrestricted stock, performance units and performance shares. The annual
bonus and long-term incentives introduce risk to the total executive
compensation package. These elements are variable, may fluctuate significantly
from year to year and are directly tied to Company and individual performance.
To ensure that Management's interest in the Company is aligned with
those of its stockholders, a portion of executive compensation is generally
delivered through equity. Equity compensation is tied to the long-term
performance of the Company and is used to provide an incentive that focuses
attention on managing the Company from an owner's perspective. Compensation tied
to equity of the Company provides a level of risk and upside opportunity that
encourages Management to achieve the Company's long-term goals and objectives.
The Compensation Committee annually reviews the competitiveness of the
Company's executive compensation programs and recommends changes, if any, to the
Board of Directors.
The Compensation Committee has reviewed the executive compensation
programs and employee benefit plans in light of Section 162(m) of the Code
("Section 162(m)"), which establishes a limit on the deductibility of annual
compensation for certain executive officers if their compensation exceeds
$1,000,000. It is the general intention of the Compensation Committee to
recommend to the Board of Directors that executive compensation will meet the
requirements for deductibility under Section 162(m).
EXECUTIVE OFFICERS' COMPENSATION
In 1996, the Board of Directors engaged KPMG Peat Marwick LLP ("KPMG")
as an outside compensation consultant to provide compensation reference points
through analysis and comparison to a group of peer companies in the medical
device industry which have significant high-technology product orientation and
similar market capitalization-to-revenue ratios (collectively, the "Peer
Companies"). The Board of Directors relied on KPMG's findings to determine that
beginning in 1997, the compensation of Management should, as an aggregate of
salary, bonus awards and stock options, follow as a guideline the median of the
Peer Companies' compensation range.
The Board of Directors granted cash bonuses to the Company's executive
officers in February 1997 in recognition of individual achievements related to
fiscal year 1996 growth and performance of the Company. In granting such
individual performance bonuses, the Board of Directors took into consideration
the early commercial stage of the Company, the business environment in which the
Company operates and the amounts of individual bonus awards granted in prior
years. No cash bonuses were granted by the Company during fiscal year 1996.
-17-
<PAGE>
The cash bonuses which may be granted with respect to fiscal year 1997 by the
Board of Directors are intended to reward both corporate and individual
performance with each such category weighted 50% of the total cash bonus award,
except in the case of the Chief Executive Officer whose cash bonus is to be
weighted 100% on the basis of corporate performance. The Board of Directors has
established targets for cash bonus awards in amounts graduated by officer level
that, when aggregated with such officer's salary and target stock option grant,
follow as a guideline the median of the Peer Companies' aggregate compensation
range for such grade level. The corporate portion of bonuses is based on
objective criteria and the individual performance portion is based on subjective
criteria. Minimum dollar thresholds for corporate performance are set by the
Board of Directors, 80% percent of which must be attained prior to the grant of
any corporate portion of the bonus award. The corporate performance portion of
the bonus awarded is pro-rated proportionate to the percentage of the threshold
target attained. The portion of the cash bonus related to individual performance
is determined by considering the executive officer's position level, the area of
responsibility and by reviewing whether such person has performed in an
outstanding manner, above expectations, meeting expectations, or below
expectations.
No stock option awards were granted in fiscal year 1996 to Named
Executive Officers. The Board of Directors has determined that beginning in
1997, stock option grants to Management, when aggregated with each executive
officer's salary and maximum potential bonus award, should follow as a guideline
the median of the Peer Companies' aggregate compensation range. The targeted
grant levels assume an annual award of stock options with an exercise price set
at the publicly traded market value of the Company's Common Stock on a fixed
date. All such options are for the purchase of Common Stock. In granting stock
option awards, the Board of Directors may also take into account prior stock
option grants in determining the number of stock options that may be granted to
each recipient.
CEO COMPENSATION
Mr. Rutenberg's employment agreement provides for a minimum annual
salary that may be increased annually at the discretion of the Compensation
Committee. Mr. Rutenberg's 1996 base salary was the same as his 1995 base
salary, without adjustment. In considering base salary adjustments to Mr.
Rutenberg's 1997 compensation, the Board of Directors intends to follow as a
guideline chief executive officer compensation of the Peer Companies. The salary
for Mr. Rutenberg reported in the Summary Compensation Table above reflects the
salary actually paid to Mr. Rutenberg in 1996.
In February of 1997, the Board of Directors granted a cash bonus of
$25,000 to Mr. Rutenberg in respect of certain goals and achievements attained
by Mr. Rutenberg and the Company during fiscal year 1996. In granting such
individual performance bonus, the Board of Directors took into consideration the
early commercial stage of the Company, the business environment in which the
Company operates and the amounts of bonus awards granted in prior years. Mr.
Rutenberg received no cash bonus during the fiscal year 1996. The Board of
Directors has determined that the criteria for granting future year cash bonuses
to Mr. Rutenberg by the Board of Directors will be based entirely on corporate
performance, as discussed in greater detail under "Executive Officers'
Compensation" above. The total cash compensation and bonus received by Mr.
Rutenberg in respect of 1996 was $200,000.
Mr. Rutenberg received no stock option grants during fiscal year 1996.
The Board of Directors has determined that stock option grants to Mr. Rutenberg
in fiscal year 1997 and future periods should follow as a guideline amounts
that, when aggregated with salary and maximum potential bonus award, are at the
median of the Peer Companies' aggregate compensation range. The targeted grant
levels assume an annual award of stock options with an exercise price set at
-18-
<PAGE>
the publicly traded market value of the Company's Common Stock on a fixed date.
Messrs. Rutenberg and Ish-Hurwitz excused themselves from all
discussions and determinations by the Board of Directors with respect to all
issues concerning their own compensation, including salary, bonus, and stock
option awards.
The foregoing Report on 1996 Executive Compensation is submitted by the
members of the 1996 Compensation Committee of the Board of Directors.
Elizabeth Cogan Fascitelli
Carl Genberg
Arthur L. Herbst, M.D.
-19-
<PAGE>
PERFORMANCE GRAPH
The graph and chart set forth below show the value of an investment of $100 from
the period beginning on December 7, 1995 (the date of the initial public
offering of the Company's Common Stock at a price of $15.00 per share) in each
of the Company's Common Stock ("NSIX"), the Standard & Poor's 500 Stock Index
(the "S&P 500"), the Nasdaq Stock Market Total Return Index ("Nasdaq") and the
Dow Jones Medical and Biotechnology Industry Group Index (the "Group Index").
The S&P 500 and the Group Index were each used as comparable performance
indicators in the Company's 1996 Proxy Statement. Because the Common Stock is
traded on the Nasdaq National Market System, the Company has added the Nasdaq
index to its performance graph and will discontinue use of the S&P 500 as a
comparable performance indicator in the Company's future Proxy Statements. All
values assume reinvestment of the pre-tax value of dividends paid by companies
included in each of these indexes and calculations as of the dates set forth
below.
[GRAPH APPEARS HERE]
Date 12/7/95 12/31/95 3/30/96 6/30/96 9/30/96 12/31/96 3/19/97
NSIX $ 100.00 $ 134.17 $145.01 $100.00 $124.17 $ 88.34 $ 57.50
S&P 500 100.00 99.96 104.76 109.13 111.55 120.22 127.52
Nasdaq 100.00 99.90 104.58 112.52 116.50 122.59 118.62
Group Index 100.00 107.08 107.64 101.00 114.05 113.69 115.06
-20-
<PAGE>
PROPOSAL 2
RATIFICATION OF APPOINTMENT OF INDEPENDENT AUDITORS
The Board of Directors has appointed Ernst & Young LLP as independent
auditors for the fiscal year ending December 31, 1997, upon the recommendation
of its Audit Committee. Ernst & Young LLP has served as auditors for the Company
since 1993. A representative of Ernst & Young LLP will be in attendance at the
Annual Meeting and will have an opportunity to make a statement if the
representative desires to do so and will be available to respond to questions
from stockholders.
Audit services of Ernst & Young LLP for 1996 included the examination of
the consolidated balance sheets of the Company and its subsidiaries and the
related consolidated statements of operations, stockholders' equity and cash
flows for each of the years ended December 31, 1994, 1995 and 1996.
Unless marked to the contrary, proxies received will be voted FOR
ratification of the appointment of Ernst & Young LLP as independent auditors for
the fiscal year ending December 31, 1997.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE IN FAVOR OF PROPOSAL 2.
-21-
<PAGE>
COMPLIANCE WITH SECTION 16 OF THE
SECURITIES EXCHANGE ACT OF 1934
Section 16(a) promulgated under the Exchange Act requires executive
officers, directors, and persons who beneficially own more than ten percent
(10%) of the Company's Common Stock to file initial reports of ownership and
reports of changes in ownership of the Company's securities with the Commission.
Based solely on a review of such information and the copies of the
filings furnished by executive officers and directors to the Company, the
Company believes that during fiscal year ended December 31, 1996, all Section
16(a) filing requirements applicable to the Company's executive officers,
directors and persons who beneficially own more than ten percent (10%) of the
Company's Common Stock were complied with except for the following to C. Raymond
Larkin, Jr., a director of the Company, whose Form 3 was due within ten days of
his appointment to the Board of Directors in February 1996 but was not filed
until five months late in July 1996; Henk Snyman, President of NSI Europe B.V.,
a subsidiary of the Company, whose Form 3 was due within 10 days of his
appointment as an officer of the Company on November 7, 1996 but was not filed
until two weeks late in November 1996; and Uzi Ish-Hurwitz, Executive Vice
President and a director of the Company, whose Form 4 was due but not filed in
January 1997 with respect to an employee stock option exercise and sale of 2,000
shares of Common Stock in December 1996 and whose Form 5 with respect to the
late reporting of such 1996 transaction was not filed with the Commission until
April 1997.
CERTAIN TRANSACTIONS
From 1989 through 1991, the Company sold various long-term territorial
license agreements (the "License Agreements") for the PAPNET(R) Testing System.
Following mergers of the entities holding the License Agreements, there
are currently two licensees. Carl Genberg, a director of the Company and member
of the Compensation Committee, has significant ownership interests in the two
licensees and is an officer and director of Cytology West, Inc., holder of the
License Agreement relating to Arizona, Nevada, Utah and San Diego County. In
connection with 1995 Settlement and Warrant Exercise Agreements with
the licensees, which clarified previously disputed elements of the License
Agreements, Mr. Genberg received 26,903 shares of Common Stock upon the
"cashless exercise" of certain warrants (such warrants had originally been
issued to an affiliate of Mr. Genberg in consideration of instrumental
assistance to the Company with respect to sales of the License Agreements). In
addition, the Company issued 89,020 shares of Common Stock pursuant to the
Settlement Agreement as an aggregate distribution to two of the original four
licensees and to Carl Genberg individually. The holders of the License
Agreements receive royalties on an annual basis which the Company estimates will
be approximately 10% of its United States revenues over the term of the License
Agreements, but there is no assurance that the amount of such royalties will not
be more or less than such percentage. The Company's aggregate royalty expense
incurred under the License Agreements was approximately $286,000 and $87,000 in
1996 and 1995, respectively. In accordance with the Settlement Agreement, the
Company will enter into revised licenses with the two licensees pursuant to
which the rights and obligations will be clarified but as to which the economic
terms will not be materially altered except that slides received from multistate
-22-
<PAGE>
national laboratories will be deemed to have been received from the licensed
territories pro rata according to each territory's population as a percentage
of United States population. The Restated Licenses will expire on December 31,
2025.
PFEL Transactions. The Company entered into an exclusive representation
agreement with Papnet (Far East) Ltd. ("PFEL") under which the Company incurred
aggregate expenses of approximately $142,000 in 1996, $136,000 in 1995 and
$116,000 in 1994. Included in such amounts are management fees paid by the
Company in connection with assistance rendered by PFEL with respect to the
establishment of the Company's Asia operations center in Hong Kong. The Company
expects to pay PFEL approximately $25,000 in management fees in 1997. Dr.
Stephen Ng, is the President and an 18.3% stockholder of PFEL. Dr. Ng is also
the President of Compuscreen Medical Diagnostic Centre ("Compuscreen"), a
subsidiary of PFEL and a customer of the Company. Dr. Ng is a Class II Director
of the Company whose term ends at the 1997 Annual Meeting and he is not standing
for reelection. The Company recorded approximately $531,000, $259,000 and
$18,000 in revenue from Compuscreen in 1996, 1995 and 1994, respectively. In
addition, PFEL was the record holder of 1,351,064 shares of the Company's
Convertible Preferred Stock, all of which automatically converted into 337,766
shares of Common Stock upon completion of the Company's initial public offering
(the "IPO"). PFEL purchased such shares of Convertible Preferred Stock in May
1994 and January 1995, in each case concurrently with other unaffiliated
investors who paid the same prices per share and received the same terms and
conditions. During the fourth quarter of 1996, PFEL proposed that the Company
purchase its business assets and those of affiliated entities, including
Compuscreen, and terminate the PFEL representation agreement in connection with
such acquisition. Negotiations for such an acquisition are continuing, but no
definitive agreement has yet been reached.
Canadian License Rights. Provisions of a promissory note dated October
3, 1990 (the "Note", which later converted to Series A Convertible Preferred
Stock and subsequently converted automatically into Common Stock upon completion
of the IPO), granted the holder of the Note certain rights to an agreement to be
the Company's sole licensee for distribution of the PAPNET(R) system in Canada
(the "Canadian rights"). The Note provides that such "licensee shall be entitled
to terms which are at least as favorable as those in any domestic United States
of America licenses." Such agreement has not been negotiated, and as of the date
hereof no amounts have been paid by the Company in respect of such Canadian
rights. Joseph Salamon, a former director of the Company whose term expired at
the 1996 Annual Meeting, is the agent of the record holder of the Canadian
rights under the Note.
Consulting Agreement. Dr. Herbst, a Class I Director of the Company, has
served as a consultant to the Company in the field of gynecological oncology
since 1994. Dr. Herbst's current consulting agreement provides for an annual
base fee of $20,000 plus expenses and additional fees for any certain special
projects. The term of his agreement ends on December 31, 1999. The Company paid
Dr. Herbst approximately $36,000, $27,500 and $20,000 in 1996, 1995 and 1994,
respectively, plus reimbursement of expenses incurred in connection with such
services.
Graphic Design Services. The Company has, in the past, utilized the
services of Insight Graphics and Design ("Insight"), the sole proprietor of
which is Ellen Rutenberg, wife of Mark Rutenberg, the President, Chairman and
Chief Executive Officer of the Company. Insight provided graphic design
consulting services to the Company, and had been responsible for the creative
design of the Company's domestic and international marketing materials from 1993
until May 1996. The Company paid Insight approximately $48,000 and $57,700 in
1995 and 1994, respectively, for such services. The Company made no payments to
Insight during 1996. In
-23-
<PAGE>
1996, Mrs. Rutenberg became an employee of the Company at an annual salary of
approximately $48,000. The Company does not anticipate utilizing Insight for any
further services.
The Company believes that the terms of the transactions described in
this section are no less favorable to the Company than the terms it would have
received if the transactions were entered into with parties unaffiliated with
the Company.
OTHER MATTERS
The entire cost of solicitation of proxies will be borne by the Company,
including preparation, assembly and mailing of this Proxy Statement, the proxy
card and other materials furnished to stockholders. Proxies may be solicited by
mail, personal interview, telephone or telegraph. Directors, officers and other
employees of the Company may solicit proxies by such methods without additional
compensation. The Company will reimburse banks, brokerage houses and other
institutions, nominees and fiduciaries for their reasonable expenses incurred in
connection with forwarding proxy material to their principals. Employees of D.F.
King & Co., Inc. will solicit proxies at a fee of approximately $2,000 plus
out-of-pocket expenses. American Stock Transfer & Trust Company will also
solicit proxies as one of the services included within their monthly fee as the
transfer agent of the Company.
As of the date of this Proxy Statement, the Company does not intend to
present and has not been informed that any other person intends to present any
business not specified in this Proxy Statement for action at the Annual Meeting.
If any other matters properly come before the Annual Meeting, proxies will be
voted on such matters in accordance with the judgment of the person or persons
authorized to vote the proxies.
COPIES OF THE COMPANY'S ANNUAL REPORT AND FORM 10-K (INCLUDING FINANCIAL
STATEMENTS THEREOF) FOR THE YEAR ENDED DECEMBER 31, 1996 MAY BE OBTAINED WITHOUT
CHARGE BY CONTACTING THE COMPANY'S INVESTOR RELATIONS CONSULTANT,
LIPPERT/HEILSHORN & ASSOCIATES, 800 THIRD AVE., SUITE 1701, NEW YORK, NY 10022,
TELEPHONE (212) 838-3777.
-24-
<PAGE>
SUBMISSION OF STOCKHOLDER PROPOSALS FOR INCLUSION
IN THE COMPANY'S 1998 PROXY STATEMENT
In accordance with Rule 14a-8 of the Commission under the Exchange Act,
stockholders may present proposals which may be proper subjects for inclusion in
the proxy statement and for consideration at an annual meeting. To be
considered, proposals must be submitted on a timely basis. It is presently
anticipated that the proxy for the 1998 Annual Meeting will be mailed on or
about April 15, 1998. Consequently, proposals for the 1998 Annual Meeting must
be received by the Company no later than December 17, 1997. Proposals, as well
as any questions related thereto, should be submitted in writing to the
Secretary of the Company. Proposals may be included in the proxy statement for
the 1998 Annual Meeting if they comply with certain rules and regulations
promulgated by the Commission.
By order of the Board of Directors,
JOHN B. HENNEMAN, III
Vice President of Corporate Development,
Secretary and General Counsel
Suffern, New York
April 15, 1997
-25-
<PAGE>
FORM OF PROXY - Side 1
NEUROMEDICAL SYSTEMS, INC.
PROXY FOR ANNUAL MEETING OF STOCKHOLDERS MAY 15, 1997
The undersigned hereby appoints John B. Henneman, III and Mark R. Rutenberg as
Proxies, each with the power to appoint his substitute, and hereby authorizes
them, to represent and vote, as designated on the reverse, all shares of common
stock of Neuromedical Systems, Inc. (the "Company") held of record by the
undersigned on April 2, 1997, at the Annual Meeting of Stockholders of the
Company to be held on May 15, 1997 or any adjournments or postponements thereof.
The undersigned hereby acknowledges receipt of the Notice of Annual Meeting of
Stockholders and Proxy Statement, dated April 15, 1997, and the 1996 Annual
Report to Stockholders.
(Continued and to be Signed on Reverse Side.)
<PAGE>
FORM OF PROXY - Side 2
A Please mark your votes as in this example __X__
1. ELECTION OF CLASS II DIRECTORS FOR all nominees (except as noted below)
____ WITHHOLD AUTHORITY to vote for all nominees ____ Nominees:
Stuart M. Essig
C. Raymond Larkin, Jr.
INSTRUCTION: To withhold authority to vote for any
nominee(s), write the name(s) on the line below.
- --------------------------------------
2. Proposal to ratify the appointment of Ernst & Young LLP as the Company's
independent auditors for the fiscal year ending December 31, 1997:
FOR ____
AGAINST ____
ABSTAIN ____
Transact such other matters as may properly come before the Annual Meeting.
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. THIS PROXY WILL BE
VOTED AS DIRECTED. IN THE ABSENCE OF DIRECTION, THIS PROXY WILL BE VOTED FOR
PROPOSALS 1 AND 2.
STOCKHOLDERS ARE URGED TO COMPLETE, SIGN, DATE AND RETURN THIS PROXY PROMPTLY IN
THE ENVELOPE PROVIDED, WHICH REQUIRES NO POSTAGE IF MAILED WITHIN THE UNITED
STATES.
Signature ____________________ _______________________
Print name and title
Date___________________, 1997
Signature ____________________ _______________________
Print name and title
Date___________________, 1997
Note: Please sign exactly as your name appears on this Proxy. If acting as
executor, administrator, trustee, guardian, etc., please indicate full title as
such when signing. If a corporation, please sign the full corporate name by duly
authorized officer. If a partnership, please sign full partnership name by
authorized person. If shares are held jointly, please have each stockholder
sign.
